Overview制癌剤投与量設定におけるパラダイムシフト : MTD VS 腫瘍サイズ Paradigm shift in dosage determination of anticancer agents.:Paradigm shift in dosage determination of anticancer agents—Dosage based on MTD to tumor size

この論文にアクセスする

この論文をさがす

著者

    • 前田 浩 MAEDA Hiroshi
    • 熊本大学医学部微生物学講座 Department of Microbiology, Kumamoto University School of Medicine

抄録

Traditional anticancer agents are mostly cytotoxic and small in molecular size. They distribute indiscriminately throughout the body, thus the high doge used in patients results in severe toxicity. Dose setting is based on maximum tolerable dose (MTD) ; and no way to escape the side effect at this dose. In contrast, polymeric drugs or microparticulates accumulate predominantly incancer tissue, if not 100%, which the mechanism is based on EPR-effect, Mechanism of EPR-effect is also described in the text. In any events, the dose should be based on the size of tumor ; large tumor needs large amount of drug. Such a good example is SMANCS/Lipiodol giver arterially for hepatoma ; this method can achieve a tumor/blood ratio of 2000, almost like missile. Accordingly, its good clinical result depends on dosing regimen based on tumor size. This concept will be appreciated as more such drugs with highly effective targeting become available.

収録刊行物

  • Drug delivery system

    Drug delivery system 17(2), 88-93, 2002-03-10

    日本DDS学会

参考文献:  34件中 1-34件 を表示

各種コード

  • NII論文ID(NAID)
    10008132134
  • NII書誌ID(NCID)
    AN10084591
  • 本文言語コード
    JPN
  • 資料種別
    REV
  • ISSN
    09135006
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ